Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer

被引:33
作者
Huo, Lei [1 ]
Zhang, Jinxia [1 ]
Gilcrease, Michael Z. [1 ]
Gong, Yun [1 ]
Wu, Yun [1 ]
Zhang, Hong [1 ]
Resetkova, Erika [1 ]
Hunt, Kelly K. [2 ]
Deavers, Michael T. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
GCDFP-15; immunohistochemistry; mammaglobin A; triple-negative; PATHOLOGISTS GUIDELINE RECOMMENDATIONS; ESTROGEN-RECEPTOR; DIAGNOSTIC MARKER; AMERICAN-SOCIETY; PRIMARY SITES; ADENOCARCINOMA; GCDFP-15; TUMORS; COEXPRESSION; NEOPLASMS;
D O I
10.1111/j.1365-2559.2012.04344.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Huo L, Zhang J, Gilcrease M Z, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt K K & Deavers M T (2013) Histopathology 62, 267-274 Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer Aims: In addition to oestrogen and progesterone receptors, gross cystic disease fluid protein-15 (GCDFP-15) and mammaglobin A (MAM) are the most common markers used to identify breast origin by immunohistochemistry. GCDFP-15 expression has been reported in approximately 60% of breast carcinomas and MAM expression in approximately 80%. Data on their expression in triple-negative breast cancer (TNBC) are very limited. The aim of this study was to examine the expression of these markers in TNBC to determine their utility in pathological diagnosis. Methods and results: We studied the immunohistochemical (IHC) expression of GCDFP-15 and MAM in 63 primary and 118 metastatic TNBCs. GCDFP-15 staining was present in 14% of primary and 21% of metastatic TNBCs. MAM staining was present in 25% of primary and 41% of metastatic TNBCs. The frequency of expression of GCDFP-15 and/or MAM was 30% in primary and 43% in metastatic TNBCs, and many positive tumours had only focal staining. Conclusions: Staining for GCDFP-15 and/or MAM in triple-negative carcinomas helps to confirm breast origin, but most tumours in this subgroup of breast carcinomas lack expression of either marker.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 32 条
[1]   Expression of human mammaglobin and clinicopathologic correlations in breast cancer: The findings in Malaysia [J].
Al-Joudi, Fawwaz S. ;
Kaid, Fahme A. K. ;
Ishak, Ismarulyusda ;
Mohamed, Norhazilah ;
Osman, Kairol ;
Alias, Iskandar Zulkarnain .
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (02) :284-289
[2]  
[Anonymous], DIS BREAST
[3]   Mammaglobin vs GCDFP-15 - An immunohistologic validation survey for sensitivity and specificity [J].
Bhargava, Rohit ;
Beriwal, Sushil ;
Dabbs, David J. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (01) :103-113
[4]  
CHAIGNAUD B, 1994, J AM COLL SURGEONS, V179, P49
[5]   Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors [J].
Chia, Shi Yun ;
Thike, Aye Aye ;
Cheok, Poh Yian ;
Tan, Puay Hoon .
BREAST, 2010, 19 (05) :355-359
[6]  
Fritzsche FR, 2007, HISTOL HISTOPATHOL, V22, P1221, DOI 10.14670/HH-22.1221
[7]   Relationship between mammaglobin expression and estrogen receptor status in breast tumors [J].
Guan, XF ;
Hamedani, MK ;
Adeyinka, A ;
Walker, C ;
Kemp, A ;
Murphy, LC ;
Watson, PH ;
Leygue, E .
ENDOCRINE, 2003, 21 (03) :245-250
[8]  
HAJDU SI, 1972, CANCER-AM CANCER SOC, V29, P1691, DOI 10.1002/1097-0142(197206)29:6<1691::AID-CNCR2820290637>3.0.CO
[9]  
2-4
[10]  
Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.5858/134.6.907, 10.1200/JCO.2009.25.6529, 10.1200/JOP.777003]